In a clinical trial (CA201) for the first-line treatment of advanced breast cancer conducted in China, the objective response rate after albumin-paclitaxel treatment reached 56%, while the control group using conventional chemotherapy drugs could only reach 27% (Guo et al., 2019). This evidence concerns the gene ALB and breast cancer.